

## Appendix A

The drugs included in the 2021 focussed evidence search are all licenced for use in adults with type 2 diabetes. These were:

<b>Drug</b>	<b>Licensing status in children in diabetes</b>	<b>Drug type</b>
glipizide, glimepiride	Not licensed	sulfonylureas
gliclazide, tolbutamide	Not licensed but listed in the BNFC	sulfonylureas
repaglinide	Not licensed	meglitinides
pioglitazone	Not licensed	Thiazolidinedione
alogliptin, linagliptin, sitagliptin, saxagliptin, vildagliptin	Not licensed	DPP-4 inhibitors
canagliflozin, dapagliflozin, empagliflozin	Not licensed	SGLT2 inhibitors
dulaglutide, lixisenatide, exenatide: Byetta® and Bydureon®	Not licensed	GLP-1 agonist
liraglutide: Victoza®	Licensed for the treatment of adults, adolescents and children aged 10 years and above	GLP-1 agonist
Insulin	Licensing depends on brands	